Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 19/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 12/20 | 1.00 |
| ▸ | LGALS9 | O00182 | 10/20 | 1.00 |
| ▸ | LGALS8 | O00214 | 6/20 | 1.00 |
| ▸ | LGALS2 | P05162 | 1/20 | 1.00 |
| ▸ | LGALS4 | P56470 | 1/20 | 1.00 |
| ▸ | LGALS7; LGALS7B | P47929 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15150623 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16231583 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16227328 | 0.89 | LGALS3 (0.82) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16227420 | 0.89 | LGALS3 (0.80) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16234129 | 0.89 | LGALS3 (0.80) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16234124 | 0.89 | LGALS3 (0.82) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16231585 | 0.89 | LGALS3 (0.80) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16231584 | 0.89 | LGALS3 (0.82) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16231590 | 0.88 | LGALS3 (0.80) | LGALS3LGALS1LGALS9LGALS8LGALS2 | |
| SCHEMBL16234114 | 0.88 | LGALS3 (0.80) | LGALS3LGALS1LGALS9LGALS8LGALS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353141-B2 | Galectoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2016-05-31 | — | — | US | claimed |
| EP-2807176-B1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2015-12-30 | — | — | EP | claimed |
| US-20140336146-A1 | Novel galectoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2014-11-13 | — | — | US | claimed |
| US-9353141-B2 | Galectoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2016-05-31 | — | — | US | disclosed |
| CN-104066743-B | Novel galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2016-04-06 | — | — | CN | disclosed |
| EP-2807176-B1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2015-12-30 | — | — | EP | disclosed |
| US-20140336146-A1 | Novel galectoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2014-11-13 | — | — | US | disclosed |
| CN-104066743-A | Novel galactoside inhibitors of galectins | GALECTO BIOTECH AB | 2014-09-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336146-A1 | Novel galectoside inhibitors of galectins | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS1 2/4885LGALS9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.